The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
EATON: A phase I trial of nazartinib (EGF816) and trametinib in EGFR-mutant (EGFRmut) non-small cell lung cancer (NSCLC).
 
Sebastian Michels
Honoraria - AstraZeneca; Janssen Oncology; Novartis; Takeda
Consulting or Advisory Role - AstraZeneca; Janssen Oncology; Novartis; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Janssen Oncology; Lilly
 
Julia Frank
No Relationships to Disclose
 
Zhendong Chen
No Relationships to Disclose
 
Enriqueta Felip
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo Europe GmbH; Gilead Sciences; GlaxoSmithKline; ITeos Therapeutics; Johnson & Johnson/Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Turning Point Therapeutics
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb; Daiichi Sankyo; Genentech; Gilead Sciences; Johnson & Johnson/Janssen; Lilly; Medical Trends; Medscape; Merck Serono; Merck Sharp & Dohme; Novartis; Peervoice; Pfizer; Regeneron; Roche
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Roche
Other Relationship - GRIFOLS
(OPTIONAL) Uncompensated Relationships - "ETOP IBCSG Partners" Member of the Scientific Committee; “Medical writing assistance for this abstract was provided by Nimisha H. Bhoola, PhD, of Nucleus Global, an Inizio Company, and funded by F. Hoffmann-La Roche Ltd.”; Member of the Scientific Advisory Committee -Hospital Universitari Parc Taulí-; SEOM (Sociedad Española de Oncología Médica), President from 2021-2023
 
Martin Sebastian
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Merck KGaA; MSD; Novartis; Pfizer; Pierre Fabre; Regeneron; Sanofi; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Gilead Sciences; Pfizer; Pierre Fabre; Regeneron; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); Gilead Sciences (Inst)
Travel, Accommodations, Expenses - Merck; Pfizer; Takeda
 
Martin Schuler
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Johnson & Johnson/Janssen; MSD; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Immunocore; Immunocore; Johnson & Johnson/Janssen; MSD; Novartis; Regeneron; Roche; Sanofi; Tacalyx
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst)
Patents, Royalties, Other Intellectual Property - Highly sensitive method for mutation detection by PCR (Inst)
 
Martin Wermke
Honoraria - Amgen; BMS GmbH & Co. KG; Boehringer Ingelheim; GWT; Janssen; Lilly; Merck Serono; Merck Serono; Novartis; Pfizer; SYNLAB
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; ImCheck therapeutics; immatics; ISA Pharmaceuticals; Lilly; Novartis; PharmaMar; Regeneron; Tacalyx; Zymeworks
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; GEMoaB; immatics; Iovance Biotherapeutics; Janssen Oncology; Merck Serono; Pfizer; Sanofi/Aventis
 
Rafael Rosell
Consulting or Advisory Role - Blueprint Medicines; Merck KGaA
 
Lucia Nogova
Honoraria - AstraZeneca; Janssen; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; BMS; Janssen; Pfizer; Roche
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Dracen (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Janssen; Pfizer; Roche
 
Lea Ruge
Consulting or Advisory Role - Amgen; Johnson & Johnson
Travel, Accommodations, Expenses - Amgen
 
Matthias Scheffler
Honoraria - Amgen; AstraZeneca/Daiichi Sankyo; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; Novartis; Pfizer; Roche; Sanofi/Aventis; Siemens Healthineers; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Janssen Oncology; Novartis; Pfizer; Roche; Sanofi/Aventis; Siemens Healthineers; Takeda
Research Funding - Amgen (Inst); BMS GmbH & Co. KG (Inst); Dracen (Inst); Janssen (Inst); Novartis (Inst); Siemens Healthineers (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Janssen; Pfizer
 
Rieke Fischer
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Janssen
 
Richard Riedel
No Relationships to Disclose
 
Inken Terjung
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Novartis (Inst); Siemens Healthcare Diagnostics (Inst)
 
Heather Scharpenseel
Travel, Accommodations, Expenses - Johnson & Johnson
 
Sabine Merkelbach-Bruse
No Relationships to Disclose
 
Jana Fassunke
No Relationships to Disclose
 
Reinhard Buettner
No Relationships to Disclose
 
Uwe Fuhr
Stock and Other Ownership Interests - Bayer
Research Funding - InfectoPharm
 
Juergen Wolf
Honoraria - Abbvie; Amgen; Amgen Astellas BioPharma; AstraZeneca; Bayer; BeiGene; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; DISCO Pharmaceuticals; Ellipses Pharma; Genmab; Janssen; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Nuvalent, Inc.; Pfizer; Regeneron; Roche; Seagen; Takeda; Turning Point Therapeutics; Zuelling Pharma
Consulting or Advisory Role - Abbvie; Amgen; Amgen; AstraZeneca; Bayer; Blueprint Medicines; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Ignyta; Janssen; Lilly; Loxo/Lilly; Merck; Mirati Therapeutics; Novartis; Nuvalent, Inc.; Pfizer; Roche; Seagen; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb; Janssen; Novartis; Pfizer
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Janssen; Merck; Mirati Therapeutics; Novartis; Pfizer; Sanofi